HIV-1 Integrase Inhibitors: An Emerging Clinical Reality

Authors: Dayam, Raveendra; Al-Mawsawi, Laith Q.; Neamati, Nouri

Source: Drugs in R&D, Volume 8, Number 3, 2007 , pp. 155-168(14)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents. The results from advanced stages of human clinical trials with IN inhibitors indicate a promising future for these compounds as a novel class of antiretroviral drugs. Success and failure of previously discovered antiretroviral drugs have taught us that there are no magic bullets in eradicating HIV. However, approval of drugs selectively targeting IN has long been awaited. There is once again a surge of interest in the field focusing on clinical development of IN inhibitors. Here, we summarise the current status of IN inhibitors under clinical development. These agents include S-1360, GSK-364735, L-870,810, L-870,812, MK-0518, GS-9137, L-900564, GS-9224, and BMS-707035. Promising antiviral activity has already been achieved with MK-0518 and GS-9137 in late-stage clinical studies.

Keywords: BMS 707035; Elvitegravir; HIV integrase inhibitors; L 870810; Raltegravir; Research and development; S 1360; S 364735

Document Type: Review article

Affiliations: 1: Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA

Publication date: 2007-01-01